New Customers Sepcial: Get 15% off, use the code "NEW15" at checkout. Shop Now!
Bioassays
TriDix Bio offers comprehensive assay development and validation services across all major therapeutic areas. These include cell-based assays, toxicity studies, and preclinical drug discovery services. Our experienced teams are proficient in a wide range of formats and technologies, ensuring that every assay is meticulously developed and optimized for robust and reproducible outcomes.
Hepatotoxicity Assessments with Human Liver Spheroids
CYP3A4 Activity
CYP3A4 is the main hepatic cytochrome P450 expressed postnatally, making up about 30% of the liver's total P450 content. It plays a crucial role in drug metabolism. The levels of detectable CYP3A4 directly reflect the liver's detoxification capacity. A significant reduction in CYP3A4 levels indicates a serious impairment of liver function.
AST/ALT Activities
Drug-induced liver injury (DILI) is a well-known condition that can present symptoms similar to both acute and chronic liver diseases. Clinically, DILI can be categorized as hepatocellular, cholestatic, or mixed, depending on liver enzyme results. Elevated levels of ALT and AST are the primary indicators of DILI, reflecting the extent of liver damage. Consequently, it is essential to monitor changes in AST and ALT levels.
Hepatotoxicity
The toxicity of a drug to cells is closely linked to changes in cell number. As a result, the number of live cells serves as a direct indicator of the extent of growth inhibition caused by the tested agents.
Cell-based assays
Cell proliferation, viability, cytotoxicity, and morphology studies
High content imaging assay
Biochemical & cellular assays, and phenotypic functional assays
Custom in vitro assay development services
Custom in Vitro Immunoassay Services
Whole Blood Activation & Cytokine Release
Human whole blood was stimulated with different concentrations of Dynabeads (left) or PHA (right), and the levels of IL-2 and IFN-γ were measured using ELISA. The results show that the secretion of both IL-2 and IFN-γ is dose-dependent in response to Dynabeads or PHA stimulation.
CD4+ T cells isolated from human whole blood of three different donors (W-20200031, 37, and 41) were co-cultured with iDC from donor W-20200029. PD-1 mAb was added at various concentrations as indicated, and human IFN-γ levels were measured by ELISA. The results show that PD-1 antibody stimulation induces IFN-γ secretion in a dose-dependent manner, with different levels of cytokine release observed between CD4+ T cells from the different donors.
Human PBMCs from two different donors (SC12353W and SC12340W) were stimulated with Dynabeads at various ratios. CD4+ and Treg (CD25+CD127-) cells were isolated using the appropriate isolation kits. The results demonstrate that, at different Dynabead ratios, activated Treg cells significantly inhibit the secretion of IFN-γ and IL-2 by CD4+ T cells.
PBMCs from different donors were incubated with SK-BR-3 cells in the presence of varying doses of Herceptin. Cytotoxicity was evaluated by measuring LDH release, with results presented as a percentage of target cell lysis. The data show that Herceptin induces a significant ADCC effect on SK-BR-3 cells in a dose-dependent manner. Additionally, PBMCs from different sources exhibit varying levels of cytotoxicity against SK-BR-3 cells.
Biomarker and Toxicity Studies
Research focusing on crucial biomarker endpoints for toxicity
Development of advanced 3D cell and tissue models, such as liver spheroids and lung organoids, tailored to evaluate specific target organs
Utilization of these models as part of a comprehensive toxicity assessment
